Virbagen canis LT
Virbagen canis LT
Authorised
- Rabies virus, strain VP12, Inactivated
- Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated
- Leptospira interrogans, serovar Canicola, strain 601903, Inactivated
Product identification
Medicine name:
Virbagen canis LT
Active substance:
- Rabies virus, strain VP12, Inactivated
- Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated
- Leptospira interrogans, serovar Canicola, strain 601903, Inactivated
Target species:
-
Dog
Route of administration:
-
Subcutaneous use
Product details
Active substance and strength:
-
Rabies virus, strain VP12, Inactivated1.00/international unit(s)1.00Dose
-
Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated833000000.00/cells1.00Dose
-
Leptospira interrogans, serovar Canicola, strain 601903, Inactivated833000000.00/cells1.00Dose
Pharmaceutical form:
-
Solution for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI07AL01
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Germany
Package description:
- Available only in German
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)
Marketing authorisation holder:
- Virbac Tierarzneimittel GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
- Virbac
Responsible authority:
- Paul-Ehrlich-Institut
Authorisation number:
- 139a/82
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
